In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

By Dennis Thompson HealthDay ReporterMONDAY, July 14, 2025 (HealthDay News) — Good news for women of a certain age: Hormone ...

SAN FRANCISCO -- In order to maximize weight loss, a GLP-1 receptor agonist may be needed both before and after bariatric ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Tirzepatide is approved by the Food and Drug Administration (FDA) for treating type 2 diabetes and obesity, akin to other GLP-1 medications such as semaglutide. The days of cheaper versions of ...

If you're following the GLP-1 ... Plans start at $249/month for semaglutide or $359/month for tirzepatide, with discounted rates available for 3-month subscriptions.

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

Novo Nordisk and Lilly have told FDA that these GLP-1 drugs are “available”, but FDA has yet to publicly verify this information. However, it can at any time.

Since the FDA considers tirzepatide “available,” stakeholders can no longer rely on the FDA’s shortage list exception ... The resolution of shortages for tirzepatide and other GLP-1 ...

Now, brand-name GLP-1 injections of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are available again. And with compounded GLP-1s largely being phased out , many people will ...

Injectable GLP-1 medication can help manage type 2 diabetes and, ... Zepbound (tirzepatide), and Saxenda (liraglutide). These medications are only available to people with a body mass index ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release ...